Table 2.
Non-comparative phase II trials on Capecitabine with either Oxaliplatin or Irinotecan combination in patients with metastatic colorectal cancer
| Author | Patients | Drugs used | Regimen | RR (%) | mTTP (mo) | MS (mo) |
| Cassidy et al[16] | 96 | Capecitabine | 2000 mg/m2 per day (days 1-14) | 55 | 7.7 | 19.5 |
| Oxaliplatin | 130 mg/m2 day 1 | |||||
| Zeuli et al[17] | 43 | Capecitabine | 2500 mg/m2 per day (days 1-14) | 44 | - | 20 |
| Oxaliplatin | 120 mg/m2 day 1 | |||||
| Borner et al[18] | 43 | Capecitabine | 2500 mg/m2 per day (days 1-14) | 49 | 5.9 | 17.1 |
| Oxaliplatin | 130 mg/m2 day 1 | |||||
| Shields et al[19] | 35 | Capecitabine | 1500 mg/m2 per day (days 1-14) | 37.1 | - | NR |
| Oxaliplatin | 30 mg/m2 day 1 | |||||
| Bajetta et al[20] | 68 | Capecitabine | 2500 mg/m2 per day (days 2-15) | 47 | 8.3 | - |
| Irinotecan | 300 mg/m2 day 1 | |||||
| Bajetta et al[20] | 66 | Capecitabine | 2500 mg/m2per day (days 2-15) | 44 | 7.6 | - |
| Irinotecan | 150 mg/m2 days 1and 8 | |||||
| Patt et al[21] | 52 | Capecitabine | 2000 mg/m2 per day (days 2-15) | 46 | 7.1 | 15.6 |
| Irinotecan | 250 mg/m2 day 1 | |||||
| Cartwright et al[22] | 49 | Capecitabine | 2000 mg/m2 per day (days 2-15) | 45 | 5.7 | 13.4 |
| Irinotecan | 240 mg/m2 day 1 | |||||
| Kim et al[23 | 43 | Capecitabine | 2000 mg/m2 per day (days 2-15) | |||
| Irinotecan | 100 mg/m2 days 1and 8 | 46.6 | NR | NR | ||
| Rosati et al[24] | 46 | Capecitabine | 1000 mg/m2 per day twice daily on days 1-14 every 3 wk | 38 | 8 | 19.3 |
| Oxaliplatin | oxaliplatin 65 mg/m2 iv days 1 and 8 | |||||
| Garcia-Alfonso et al[25] | 53 | Capecitabine | 1000 mg/m2/d twice daily on days 2-8 every 2 wk | 32 | 9 | 19.2 |
| Irinotecan | irinotecan 175 mg/m2 on day 1 |
RR: Response rate; mTTP: Median time to progression; MS: Median survival; NR: Not recorded. All capecitabine doses were divided equally and dosed twice daily. Regimens were administered every 3 wk.